Muscle strength, joint range of motion, and gait in children and adolescents with osteogenesis imperfecta

Pediatric Physical Therapy

Volumn 26, Issue 2, 2014, Pages 245-252

  Brizola, Evelise ^a   Staub, Ana Lúcia Portella ^b   Félix, Têmis Maria ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; BONE DENSITY; BRAZIL; CHILD; CROSS-SECTIONAL STUDY; FEMALE; FRACTURES, BONE; GAIT; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MUSCLE STRENGTH; OSTEOGENESIS IMPERFECTA; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; WALKING DIFFICULTY;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BRAZIL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FRACTURES, BONE; GAIT; HUMANS; MALE; MOBILITY LIMITATION; MUSCLE STRENGTH; OSTEOGENESIS IMPERFECTA; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX;

EID: 84897499770     PISSN: 08985669     EISSN: 1538005X     Source Type: Journal    
DOI: 10.1097/PEP.0000000000000042     Document Type: Article

References (65)

1. Engelbert RH, Pruijs HE, Beemer FA, Helders PJ. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil. 1998;79:1590-1594.
2. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377-1385.
3. Venturi G, Tedeschi E, MottesM, et al. Osteogenesis imperfecta: clinical, biochemical and molecular findings. Clin Genet. 2006;70:131-139.
4. Cheung MS, Glourieux FH. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008;9:253-260.
5. Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009;11:375-385.
6. Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effecting the transition from adolescent to adult medical care. JMusculoskelet Neuronal Interact. 2012;12(1):24-27.
7. Glorieux FH. Osteogenesis imperfecta. Best Pract Res Clin Rheumatol. 2008;22(1):85-100.
8. Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367-381.
9. Rauch F, Lilac L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2010;25(6):1367-1374.
10. Ben Amor M, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;540178.
11. Van Dijk FS, Byers PH, Dalgleish R, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Med Genet. 2012;20:11-19.
12. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116.
13. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53: 1-5.
14. Tolo VT. Orthopaedic treatment of fractures in children who have multiple injuries. J Bone Joint Surg Am. 2000;82A(2):272-280.
15. Santili C, Akkari M, Waisberg G, Júnior JOC, Ferreira WM. Clinical, radiographic and laboratory evaluation of patients with osteogenesis imperfecta. Rev Assoc Med Bras. 2005;51:214-220.
16. Glorieux FH. Treatment of osteogenesis imperfecta: who, why, what? Horm Res. 2007;68:8-11.
17. Watzl MTP, Abreu AV, Kruse R. Surgical treatment of deformities and fractures on lower limbs with osteogenesis imperfecta. Acta Ortop Bras. 2009;17(4):202-206.
18. Engelbert RH, Beemer FA, van der Graaf Y, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability-a follow-up study. Arch Phys Med Rehabil. 1999;80(8):896-903.
19. Zeitlin L, Rauch F, Plotkin H, Glorieux F. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111:1030-1036.
20. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005;20(5):758-763.
21. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977-986.
22. Vallo F, Rodriguez-Leyva F, Soriano JR. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of longterm intravenous pamidronate therapy. Acta Paediatr. 2006;95: 332-339.
23. Alharbi M, Pinto G, Finidori G, et al. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res. 2009;71:38-44.
24. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4: 1-63.
25. Bishop N, Harrison R, Ahmed F, et al. A randomized, controlled doseranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res. 2010;25(1):32-44.
26. De Graaff F, Verra W, Pruijs JE, Sakkers RJ. Decrease in outpatient department visits and operative interventions due to bisphosphonate in children with osteogenesis imperfecta. J Child Orthop. 2011;5:121-125.
27. Zerbini AFC, Pippa MGB, Eis SR, et al. Clinical densitometry- official positions 2006. Rev Bras Reumatol. 2007;47(1):25-33.
28. Carter C, Wilkinson J. Persistent joint laxity and congenital dislocation of the hip. J Bone Joint Surg Br. 1964;54:40-45.
29. Beighton P, Horan S. Orthopaedic aspects of the Ehlers-Danlos syndrome. J Bone Joint Surg Br. 1969;51:444-453.
30. Bayley N. Bayley Scales of Infant Development. New York: Psychological Corp; 1969.
31. Tecklin JS. Pediatric Physical Therapy. 3th ed. Porto Alegre, Brazil: Artmed; 2002.
32. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111-122.
33. Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr. 2006;148:456-460.
34. Kendall H, Kendall F, Wadsworth G. Muscle Testing and Function. Baltimore, MD: Williams & Wilkins; 1993.
35. Medical Research Council. Aids to the Investigation of Peripheral Nerve Injuries.War memorandum. 2nd ed. London:Medical Research Council; 1943.
36. Len C, Ferraz MB, Goldenberg J, et al. Pediatric Escola Paulista de Medicina Range of Motion Scale: a reduced joint count scale for general use in juvenile rheumatoid arthritis. J Rheumatol. 1999;26(4):909-913.
37. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17(1): 30-38.
38. Roughley PJ, Rauch F, Glourieux FH. Osteogenesis imperfecta- clinical and molecular diversity. Eur Cell Mater. 2003;5:41-47.
39. Fano V, Rodríguez Celin M, Del Pino M, et al. Osteogenesis imperfecta. Clinical, functional and multidisciplinary evaluation of 65 patients. An Pediatr Barc. 2010;72(5):324-330.
40. Greeley CS, Donaruma-Kwoh M, Vettimattam M, Lobo C, Williard C, Mazur L. Fractures at diagnosis in infants and children with osteogenesis imperfecta. J Pediatr Orthop. 2013;33(1):32-36.
41. Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008;20(1):52-57.
42. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
43. Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94(2):400-409.
44. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine. 2005;72(4):313-318.
45. Rauch F, Glorieux FH. Treatment of children with osteogenesis imperfecta. Curr Osteoporosis Rep. 2006;4(4):159-164.
46. Smith LB, Thelen E. Development as a dynamic system. Trends Cogn Sci. 2003;7(8):343-348.
47. Chagas SC, ManciniMC, Fonseca ST, Soares TB, Gomes VP, Sampaio RF. Neuromuscular mechanisms and anthropometric modifications in the initial stages of independent gait. Gait Posture. 2006;24(3):375-381.
48. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ. Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000;137(3):397-402.
49. Wolf H, SarahrudiK, Vécsei V. Intramedullary osteosynthesis for fracture associated with osteogenesis imperfecta. Injury. 2009;40(3):315-320.
50. Abulsaad M, Abdelrahman A. Modified Sofield-Millar operation: less invasive surgery of lower limbs in osteogenesis imperfecta. IntOrthop. 2009;33(2):527-532.
51. Lund AM, Hansen M, Kollerup G, Juul A, Teisner B, Skovby F. Collagen derived markers of bone metabolism in osteogenesis imperfecta. Acta Pediatr. 1998;87(11):1131-1137.
52. Oliveira ATR, Junior JLFO, Junior CBR. Prevalence of coxa vara in patients with osteogenesis imperfecta. R Into. 2007;5(1):1-34.
53. Aarabi M, Rauch F, Hamdy RC, Fassier F. High prevalence of coxa vara in patients with severe osteogenesis imperfecta. J Pediatr Orthop. 2006;26(1):24-28.
54. Beighton PH, Grahame R, Bird H. Hypermobility of Joints. 2nd ed. London: Springer-Verlag; 1989.
55. Araújo CGS. Correlation among different linear and dimensionless methods of joint motion evaluation. Rev Bras Cien e Mov. 2000;8(2):27-34.
56. Cohen BA, Geraghty MT, Violand R, Rowe PC. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. J Pediatr. 2002;141(3):421-425.
57. Lamari NM, Chueire AG, Cordeiro JA. Analysis of joint mobility patterns among preschool children. Sao Paulo Med J. 2005;123(3):119-123.
58. Moraes DA, Baptista CA, Crippa JA, Louzada-Junior P. Translation into Brazilian Portuguese and validation of the five-part questionnaire for identifying hypermobility. Rev Bras Reumatol. 2011;51(1): 53-69.
59. Forléo LH, Hilário MO, Peixoto AL, Naspitz C, Goldenberg J. Articular hypermobility in school children in Sao Paulo, Brazil. J Rheumatol. 1994;20(5):916-917.
60. Subramanyam V, Janaki KV. Joint hypermobility in South Indian children. Indian Pediatr. 1996;33(9):771-772.
61. Roberto AM, Terreri MTR, Szejnfeld V, Hilário MO. Bone mineral density in children. Association with musculoskeletal pain and/or joint hypermobility. J Pediatr. 2002;78(6): 523-528.
62. Hanewinkel-van Kleef IB, Helders PJM, Takken T, Engelbert RH. Motor performance in children with generalized hypermobility: the influence of muscle strength and exercise capacity. Pediatr Phys Ther. 2009;21:194-200.
63. Caudill A, Flanagan A, Hassani S, et al. Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta. Pediatr Phys Ther. 2010;22:288-295.
64. Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil. 2004;85(5):772-778.
65. Aglan MS, Hosny L, El-Houssini R, et al. A scoring system for the assessment of clinical severity in osteogenesis imperfecta. J Child Orthop. 2012;6:29-35.